Ticker LaunchUplisting · ARTL
Artelo Biosciences, Inc.
Formerly REACTIVE MEDICAL INC.; KNIGHT KNOX DEVELOPMENT CORP.
Artelo Biosciences, Inc. (ARTL), already reporting to the SEC, moved up to Nasdaq Capital Market on Jun 25, 2019 with an offering at $6.15 per share raising $8M. Maxim Group was lead-left underwriter, joined by Joseph Gunnar. Wilson Sonsini and Fennemore Craig advised the company.
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company developing treatments that modulate the endocannabinoid system, including a cannabidiol cocrystal. Its candidate ART27.13 is entering a Phase 1b/2a trial for cancer-related anorexia, and ART26.12 is a late pre-clinical cancer therapeutic candidate.
- Status
- Uplisting
- Ticker
- ARTL
- Exchange
- Nasdaq Capital Market
- Listed
- Jun 25, 2019
- Price
- $6.15
- Raised
- $8M
- Market cap at IPO price
- $21M
- First filed
- Oct 8, 2014
- Underwriters
- Maxim Group and Joseph Gunnar
- Company counsel
- Wilson Sonsini and Fennemore Craig
- Sector
- Biotech & pharma
- Country / state
- CA
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Oct 8, 2014
- Latest amendment Jun 20, 2019
- Final prospectus (424B4) Jun 25, 2019
- All filings on EDGAR CIK 1621221
Other Biotech & pharma uplistings in 2019
- BioCardia, Inc.BCDA · Aug 5, 2019 · $10M
- Guardion Health Sciences, Inc.GHSI · Apr 8, 2019 · $5M
- Chemomab Therapeutics Ltd.ANCN · Feb 13, 2019 · $30.5M